Biologic dose reduction in rheumatoid arthritis: what do patients think? Results from a patient and public involvement event
Biologic dose reduction in rheumatoid arthritis: what do patients think? Results from a patient and public involvement event
Abstract: Background: Biological therapies are well established and effective treatments for rheumatoid arthritis (RA). Although it seems impossible to stop biological therapies for the majority of RA patients with established disease it appears that dose reduction can be successful in some patients in remission or with low disease activity. Stratified medicine approaches may identify individuals who are most likely to maintain low levels of disease activity on a reduced biological therapy dose while achieving the same clinical benefit. Dose reduction may allow a reduced risk of adverse events and also produce economic benefits that may allow greater numbers of patients to use biological therapies. Despite an increased interest in biological therapy dose reduction in recent years, the perspectives of patients have not yet been reported. Engagement of patients in shared decision-making about their disease management is vital to improving health outcomes and a stated aim of many treatment guidelines. We aimed to investigate the views of patients with regard to biological therapies and dose reduction.
Methods: We arranged a patient and public involvement (PPI) event with 9 patients (8 female, mean age 49y, mean disease duration 17y) with RA. Eight patients were on a biological therapy with 2 patients on a reduced dose. Discussion was facilitated and recorded by two PPI experts and a consultant rheumatologist. Participants (1) discussed biological therapy in general, (2) listed the top 10 concerns about biological therapy and (3) explored attitudes towards dose reduction.
Results: The most common issues arising during group discussion about biological therapies in general were: impact of disease on health, delays in accessing treatment, need for education about biological therapies, adverse effects, inefficacy of previous treatments, impact of disease on family and work and patient autonomy. When exploring attitudes towards dose reduction, the most common concerns were loss of disease control, delay in access to the previous dose and potential loss of efficacy of a previously successful treatment. Perceived benefits were a lower risk of adverse effects and reduced frequency of injection.
Conclusion: Patients were generally prepared to consider dose reduction but need reassurance about rapid access to higher doses should their disease flare. The data provide insight into patients’ beliefs and attitudes towards biological therapies and dose reduction and will be used to generate a questionnaire to be distributed to a larger group of patients.
i187-i187
Wallis, Dinny
31a043f9-e1af-4ffb-8593-6b9c8c29876e
Holroyd, Chris
bd50c028-34f5-493c-86da-eeb5f7ea9e78
Sonpal, Kate
f4d893d4-0862-4e9e-ac27-ad171f1762d4
Zarroug, Jalaa
64d74476-5d9c-485d-aab2-e8f75365dbae
Adams, Jo
6e38b8bb-9467-4585-86e4-14062b02bcba
Edwards, Chris
dcb27fec-75ea-4575-a844-3588bcf14106
24 April 2016
Wallis, Dinny
31a043f9-e1af-4ffb-8593-6b9c8c29876e
Holroyd, Chris
bd50c028-34f5-493c-86da-eeb5f7ea9e78
Sonpal, Kate
f4d893d4-0862-4e9e-ac27-ad171f1762d4
Zarroug, Jalaa
64d74476-5d9c-485d-aab2-e8f75365dbae
Adams, Jo
6e38b8bb-9467-4585-86e4-14062b02bcba
Edwards, Chris
dcb27fec-75ea-4575-a844-3588bcf14106
Wallis, Dinny, Holroyd, Chris, Sonpal, Kate, Zarroug, Jalaa, Adams, Jo and Edwards, Chris
(2016)
Biologic dose reduction in rheumatoid arthritis: what do patients think? Results from a patient and public involvement event.
[in special issue: Rheumatology 2016 Abstracts]
Rheumatology, 55, supplement 1, .
(doi:10.1093/rheumatology/kew166.006).
Abstract
Abstract: Background: Biological therapies are well established and effective treatments for rheumatoid arthritis (RA). Although it seems impossible to stop biological therapies for the majority of RA patients with established disease it appears that dose reduction can be successful in some patients in remission or with low disease activity. Stratified medicine approaches may identify individuals who are most likely to maintain low levels of disease activity on a reduced biological therapy dose while achieving the same clinical benefit. Dose reduction may allow a reduced risk of adverse events and also produce economic benefits that may allow greater numbers of patients to use biological therapies. Despite an increased interest in biological therapy dose reduction in recent years, the perspectives of patients have not yet been reported. Engagement of patients in shared decision-making about their disease management is vital to improving health outcomes and a stated aim of many treatment guidelines. We aimed to investigate the views of patients with regard to biological therapies and dose reduction.
Methods: We arranged a patient and public involvement (PPI) event with 9 patients (8 female, mean age 49y, mean disease duration 17y) with RA. Eight patients were on a biological therapy with 2 patients on a reduced dose. Discussion was facilitated and recorded by two PPI experts and a consultant rheumatologist. Participants (1) discussed biological therapy in general, (2) listed the top 10 concerns about biological therapy and (3) explored attitudes towards dose reduction.
Results: The most common issues arising during group discussion about biological therapies in general were: impact of disease on health, delays in accessing treatment, need for education about biological therapies, adverse effects, inefficacy of previous treatments, impact of disease on family and work and patient autonomy. When exploring attitudes towards dose reduction, the most common concerns were loss of disease control, delay in access to the previous dose and potential loss of efficacy of a previously successful treatment. Perceived benefits were a lower risk of adverse effects and reduced frequency of injection.
Conclusion: Patients were generally prepared to consider dose reduction but need reassurance about rapid access to higher doses should their disease flare. The data provide insight into patients’ beliefs and attitudes towards biological therapies and dose reduction and will be used to generate a questionnaire to be distributed to a larger group of patients.
Text
BSR 2016 Biologic dose reduction BSR 2016.docx
- Other
Slideshow
BSR 2016Dose reduction e-poster BSR 2016_28Feb.ppt
- Other
More information
e-pub ahead of print date: 24 April 2016
Published date: 24 April 2016
Organisations:
Physical & Rehabilitation Health
Identifiers
Local EPrints ID: 394135
URI: http://eprints.soton.ac.uk/id/eprint/394135
ISSN: 1462-0324
PURE UUID: 9a4f0478-582c-4ebc-8c7c-c60247583512
Catalogue record
Date deposited: 12 May 2016 08:43
Last modified: 15 Mar 2024 02:49
Export record
Altmetrics
Contributors
Author:
Dinny Wallis
Author:
Chris Holroyd
Author:
Kate Sonpal
Author:
Jalaa Zarroug
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics